intrinsic abnormalities of the coronary circulation. A reduction of maximal vasodilator capacity by calcium channel antagonists could also constitute an important anti-ischemic mechanism of action of these agents. To evaluate the effect of calcium channel antagonists on coronary flow reserve in awake humans, we measured coronary flow reserve using the coronary Doppler catheter and intracoronary papaverine at baseline and after diltiazem administered by intravenous (125 or 250 ,ug/kg bolus, 5 ,ug/kg/min infusion, n=8) or intracoronary (150-600 ,ug bolus, n=10) routes. Intravenous diltiazem reduced heart rate from 77±18 to 72±17 beats/min (mean±SD, p<0.005) and reduced mean arterial pressure from 96±11 to 86±15 mm Hg (p<0.005). Intravenous diltiazem resulted in a small decrease in coronary flow reserve (peak-to-resting flow velocity ratio) from 3.9±1.2 to 3.6±1.1 (p<0.01). After intracoronary diltiazem, mean arterial pressure was unchanged (control 99±12 mm Hg, diltiazem 97±13 mm Hg), and heart rate was maintained constant by atrial pacing. Coronary flow reserve was unchanged at 3.8±0.9 at baseline and after intracoronary diltiazem. Thus, treatment with diltiazem does not invalidate the measurement of coronary flow reserve for diagnostic purposes. Furthermore, these results suggest that attenuation of maximal coronary dilation by diltiazem is not a mechanism responsible for its antianginal efects. (Circulation 1989; 80:1240 -1246 C oronary flow reserve is a useful index of the vasodilator capacity of the coronary circulation. This measurement has been used primarily to assess the physiologic significance of coronary stenoses,1 as well as evaluate the results of coronary angioplasty2 and coronary bypass surgery.3 A limitation to the use of coronary flow reserve is that factors independent of coronary stenosis, such as hemodynamic status, left ventricular hypertrophy, and pharmacologic agents, may also alter measured coronary flow reserve. 4 Calcium heart rate, and electrocardiogram were continuously recorded on a multichannel recorder. After measurements of resting coronary bloodflow velocity, 6-10 mg papaverine hydrochloride (2 mg/ml 0.9% saline) was injected through the guiding catheter into the coronary ostium and the resultant increase in coronary blood flow velocity was recorded. To confirm that a dose of papaverine produced maximal hyperemia, coronary blood flow velocity was recorded during administration of an additional papaverine dose 2-4 mg larger than the previous dose. The maximal dose of papaverine administered was 12 mg into the left coronary artery and 8 mg into the right coronary artery in all patients. Flow velocity was allowed to return to baseline levels between doses of papaverine. Coronary flow reserve was calculated as the quotient of the peak mean flow velocity (kHz shift) after intracoronary papaverine and the resting mean flow velocity during the 15-30 seconds preceding papaverine administration. Coronary flow reserve measurement was repeated after diltiazem using the largest dose of intracoronary papaverine administered during baseline coronary flow reserve measurement.
Quantitative Coronary Angiography
Coronary arteriography was performed with meglumine diatrizoate 76% in a projection that allowed visualization of the arterial segment that contained the Doppler catheter with minimal vessel foreshortening and overlap. No coronary contrast was injected during the 3 minutes before each angiogram. Angiograms were analyzed by the Pie Data-Reiber method of quantitative coronary angiography. This method has been described in detail elsewhere.11 Briefly, a 35-mm cinefilm frame was digitized to a 1,330x1,770 pixel matrix containing 256 gray levels. After the operator identified the limits of the coronary catheter and arterial segment to be analyzed, the edges of these structures were automatically detected, and the arterial size was corrected for magnification and pincushion distortion. A 1-2-mm long proximal segment of the artery cannulated by the Doppler catheter that was adjacent to a vascular landmark was manually identified and mean segment diameter was determined by computer. Measurements 
Results

Effect of Intravenous Diltiazem on
Systemic Hemodynamics
Intravenous diltiazem infusion resulted in a blood diltiazem level of 263+±89.5 ng/ml (n=6) and was similar in the three patients receiving the 250 ,Lg/kg (301±65 ng/ml) and the three receiving 125 ,ug/kg (224±107 ng/ml) loading doses. During intravenous diltiazem infusion, mean arterial pressure decreased from 96±+11 to 86±+15 mm Hg (p<0.005) (Figure 1) Baseline coronary flow reserve (peak to resting flow velocity ratio) was 3.9±1.2 ( Figure 2) . During the intravenous diltiazem-loading dose, coronary flow velocity reached a maximum of 1.24+0.39 times the baseline coronary flow velocity (p<0. 1) and returned to baseline (1.01±0.10 times baseline coronary flow velocity, p =NS) within 5 minutes of completing the loading dose. The coronary flow reserve during diltiazem infusion, 3.6+1.1, was slightly decreased (p<O.Ol) from the baseline flow reserve (Figure 2 ). Mean diameter of the coronary artery segment that contained the Doppler catheter increased from 3.03±0.64 to 3.31±0.59 mm (n=7,p<0.025).
Effect of Intracoronary Diltiazem on Systemic Hemodynamics
During intracoronary diltiazem administration, heart rate was maintained by atrial pacing at 80 beats/min in four patients and 90 beats/min in six patients. Transient asymptomatic second-degree atrioventricular block developed in two patients during intracoronary infusion. Mean arterial pressure at baseline was 99±+12 mm Hg and was unchanged after intracoronary diltiazem at 97±13 mm Hg (p=NS) (Figure 3 ).
Effect of Intracoronary Diltiazem on Coronary Flow Reserve and Coronary Artery Diameter
A representative recording of coronary flow velocity and flow reserve before and after intracoronary diltiazem is shown in Figure 4 , and the results for all patients are summarized in Figure 5 . Baseline coronary flow reserve (peak to resting flow velocity ratio) was -3.8+0.9 ( Figure 5 ). During the intracoronary diltiazem infusion of the largest dose of diltiazem, coronary flow velocity increased to a maximum of 2.02+±0.74 times the baseline coronary flow velocity (p<0.005) and returned to baseline (0.96±0.12 times baseline coronary flow velocity, p=NS) within 5 minutes of completing the infusion. The coronary flow reserve after the largest dose of intracoronary diltiazem, 3.8+0.9, was unchanged from the baseline flow reserve ( Figure 5 ). Intracoronary diltiazem had no effect on coronary flow reserve at any of the doses administered (600 gg peak dose: control, 4.3+0.8; diltiazem, 4.3+0.8; 300 gg peak dose: control, 3.2+0.6; diltiazem, 3.3+0.8; 150 ,ug peak dose: control, 2.8+0.1; diltiazem, 2.9±0.2).
The diameter of the coronary artery segment that contained the Doppler catheter increased from 3.21±0.42 to 3.40±0.49 mm (n=8,p<0.05). tration of the calcium channel antagonist, diltiazem, to patients produces a small reduction in coronary flow reserve. This minimal effect was observed after intravenous administration of diltiazem in doses resulting in plasma levels that equal or exceed those typically occurring after high-dose oral therapy.12 250 mcgskg Decreases in heart rate and arterial pressure were similar to those previously reported after intrave-125 mcglkg nous diltiazem.13,14 Coronary flow reserve was **~* botus unchanged after intracoronary diltiazem administration in doses that produced larger transient increases in coronary flow velocity than intravenous diltiazem produced but no changes in heart rate or baseline and arterial pressure. This suggests that the small decrease in coronary flow reserve after intravenous sured in individual coronary arteries by the coronary Doppler catheter accurately reflect changes in coronary blood flow, and that the catheter does not produce physiologically detectable obstruction. In this study, both intravenous and intracoronary diltiazem resulted in a small increase in proximal coronary artery diameter. Therefore, at a time when resting flow velocity had returned to baseline after diltiazem, volumetric flow was increased. Augmentation of resting coronary flow would favor a decrease in coronary flow reserve after diltiazem. However, the present study demonstrated only a small decrease in coronary flow reserve after intravenous diltiazem and no change after intracoronary diltiazem.
Though coronary vasodilation is generally believed to improve the balance of myocardial oxygen supply and demand, a proischemic effect of vasodilation has been described. The dilation of myocardial resistance vessels distal to a flow-limiting coronary stenosis may increase total coronary flow, leading to a larger pressure drop across the coronary lesion.8 This fall in distal coronary perfusion pressure may produce subendocardial ischemia despite elevated global coronary flow. Supporting this concept is the observation that patients with severe obstructive coronary lesions commonly develop angina and segmental left ventricular dysfunction when given a potent dilator of coronary resistance vessels such as intravenous dipyridamole.15 This "coronary steal" effect may also develop during metabolic, as well as pharmacologic coronary vasodilation. 16 Consequently, subendocardial myocardial ischemia during exercise may be worsened by metabolically mediated dilatation of coronary vasculature with resultant reduction in perfusion pressure distal to flow-limiting lesions. Because calcium channel antagonists have been shown to blunt maximal coronary flow after a variety of stimuli in animals, a potential mode of anti-ischemic action of these agents might be to attenuate meta---bolically mediated dilatation of resistance vessels in nonischemic regions. The present study, which demonstrates minor changes in coronary flow reserve with intravenous diltiazem that may be due to its systemic hemodynamic effects, suggests that reduction in coronary steal by attenuation of coronary hyperemia during exercise is not an important anti-ischemic mechanism of calcium channel antagonists in humans.
Our results are at variance with studies in dogs demonstrating markedly reduced maximal hyperemia after calcium channel-antagonist administration.5-7 In these studies, blunting of maximal coronary flow was observed after treatment with diltiazem, nifedipine, and other calcium channel antagonists in both conscious and anesthetized animals. The effect was observed with reactive hyperemia after transient coronary occlusion and during pharmacologic coronary vasodilation with intracoronary adenosine. The present study was conducted with intracoronary papaverine, which is the most commonly used coronary vasodilator for measurement of coronary flow reserve in humans. A potential explanation of the discrepancy between our results and those in dogs is a selective effect of calcium channel antagonists on coronary dilation occurring with brief coronary occlusion or adenosine administration but not after intracoronary papaverine. Another possible explanation is a species difference in the effect of diltiazem on the coronary circulation.
Limited human studies have also revealed modest reduction in coronary vasodilator responses after intravenous diltiazem17 and investigational calcium channel antagonist bepridil18 in patients with coronary atherosclerosis. However, interpretation of theses studies is limited by methodologic deficiencies. Coronary blood flow was measured by coronary sinus thermodilution, a technique with many limitations particularly in patients with coronary disease. 19, 20 In addition, coronary flow was measured after intracoronary injection of radiographic contrast material, a submaximal coronary vasodilator.°0
There are two clinical implications of this study. First, treatment of patients with diltiazem does not invalidate the measurement of coronary flow reserve for diagnostic purposes. This lack of effect on coronary flow reserve may also pertain to other calcium channel antagonists. However, because the relative vasodilator and myocardial depressant activities of these agents vary widely, other calcium channel antagonists may have different effects on coronary flow reserve. Second, our results suggest that reduction in coronary steal by attenuation of coronary hyperemia during exercise is not an important antiischemic mechanism of calcium channel antagonists.
